KR20240134962A - 암 치료를 위한 바이사이클릭 트리아진 유도체 - Google Patents

암 치료를 위한 바이사이클릭 트리아진 유도체 Download PDF

Info

Publication number
KR20240134962A
KR20240134962A KR1020247026963A KR20247026963A KR20240134962A KR 20240134962 A KR20240134962 A KR 20240134962A KR 1020247026963 A KR1020247026963 A KR 1020247026963A KR 20247026963 A KR20247026963 A KR 20247026963A KR 20240134962 A KR20240134962 A KR 20240134962A
Authority
KR
South Korea
Prior art keywords
salt
trifluoromethyl
cancer
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247026963A
Other languages
English (en)
Korean (ko)
Inventor
카이 테데
필립 부흐그라버
게르하르트 지마이스터
파트릭 슈타이게만
안트예 마르그렛 벤그너
울프 뵈머
필립 리나우
프랑크 베스터만
한노 글림
프리데리케 헤르브스트-노브로우치
세바스티안 디터
지나 크레트
Original Assignee
도이체스 크렙스포르슝스첸트룸
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도이체스 크렙스포르슝스첸트룸 filed Critical 도이체스 크렙스포르슝스첸트룸
Publication of KR20240134962A publication Critical patent/KR20240134962A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247026963A 2022-01-11 2023-01-06 암 치료를 위한 바이사이클릭 트리아진 유도체 Pending KR20240134962A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22150829.4 2022-01-11
EP22150829 2022-01-11
PCT/EP2023/050208 WO2023135057A1 (en) 2022-01-11 2023-01-06 Bicyclic triazine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20240134962A true KR20240134962A (ko) 2024-09-10

Family

ID=79927598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247026963A Pending KR20240134962A (ko) 2022-01-11 2023-01-06 암 치료를 위한 바이사이클릭 트리아진 유도체

Country Status (9)

Country Link
US (1) US20250066370A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463458A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502240A (cg-RX-API-DMAC7.html)
KR (1) KR20240134962A (cg-RX-API-DMAC7.html)
CN (1) CN118541372A (cg-RX-API-DMAC7.html)
AU (1) AU2023207765A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246440A1 (cg-RX-API-DMAC7.html)
IL (1) IL313835A (cg-RX-API-DMAC7.html)
WO (1) WO2023135057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CA3174507A1 (en) 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12

Also Published As

Publication number Publication date
CN118541372A (zh) 2024-08-23
WO2023135057A1 (en) 2023-07-20
CA3246440A1 (en) 2023-07-20
EP4463458A1 (en) 2024-11-20
IL313835A (en) 2024-08-01
AU2023207765A1 (en) 2024-07-04
JP2025502240A (ja) 2025-01-24
US20250066370A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
EP3532474B1 (en) 4,5-annulated 1,2,4-triazolones
EP3661517B1 (en) Dihydrooxadiazinones
CA3137472A1 (en) Acyl sulfonamides for treating cancer
AU2021231312A1 (en) Imidazotriazines acting on cancer via inhibition of CDK12
CN107949557B (zh) 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
EP3710456B1 (en) Macrocyclic indole derivatives
EP4229045A1 (en) Substituted acyl sulfonamides for treating cancer
US12427153B2 (en) 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
EP4114837A1 (en) Pyrazolopyrazines acting on cancers via inhibition of cdk12
US20230117034A1 (en) Pyrazolotriazines
WO2020126968A2 (en) Urea derivatives
WO2017202817A9 (en) [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones
WO2023135057A1 (en) Bicyclic triazine derivatives for the treatment of cancer
WO2018114670A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
WO2020157199A1 (en) Annulated dihydropyridazinone compounds as anti-cancer compounds
HK40085534A (en) Imidazotriazines acting on cancer via inhibition of cdk12
WO2020157236A1 (en) Pyridyl substituted dihydrooxadiazinones
HK40060627A (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2018114672A1 (en) [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones
EP3555101A2 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones

Legal Events

Date Code Title Description
PG1501 Laying open of application